A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Principal Institutions: Dana Farber Cancer Institute in partnership with the Pacific Pediatric Neuro Oncology Consortium (PNOC). Oncogenic dysregulation of the RAS/RAF/MEK/ERK pathway has been described in a number of diverse malignancies, […]